This report is submitted pursuant to Senate Bill 298 of the 2022 Regular Legislative Session, which requires the Louisiana Department of Health (LDH) to conduct an annual review of all medications and forms of treatment for sickle cell disease (SCD) that are eligible for coverage under the Louisiana Medicaid program.